Compare ASTC & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTC | XCUR |
|---|---|---|
| Founded | 1984 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 9.2M |
| IPO Year | 2020 | 2017 |
| Metric | ASTC | XCUR |
|---|---|---|
| Price | $4.82 | $1.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.8K | ★ 39.0K |
| Earning Date | 11-12-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2600.00 | 83.37 |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $1,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $44.02 |
| P/E Ratio | $21.40 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.92 | $0.88 |
| 52 Week High | $68.85 | $9.48 |
| Indicator | ASTC | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 32.20 | 42.41 |
| Support Level | $4.63 | $0.99 |
| Resistance Level | $7.76 | $1.52 |
| Average True Range (ATR) | 0.41 | 0.13 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 19.55 | 29.38 |
Astrotech Corp is a science and technology company. It creates, operates and scales businesses through its subsidiaries and technology platforms, including space-related technology, instrumentation, mass spectrometry, gas chromatography, process-control and environmental analysis technologies. It is evaluating opportunities to identify, develop and commercialize technologies with potential applications in space, defense, industrial, environmental, quantum computing, AI, semiconductor materials, lunar infrastructure and related markets. Its products include Tracer 1000 ETD, tracer 1000 NTD, Labrador HHGC, Fenceline GC, AgLab 1000-D2, among others. It operates in single segment.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.